Drug Trial Radar · NCT07890870
A Study to Evaluate a Single Dose of IBIO-610 in Participant With Obesity.
Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
32
Planned (sponsor's estimate)
Start
Dec 2026
Primary completion
Jan 2028
Study completion Jan 2028
Sponsor
- Lead sponsor
- iBio, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn which dose of study drug IBIO-610 has the right balance of safety, tolerability and impact on body composition in participants with obesity.
Conditions
- Obesity & Overweight
Interventions
IBIO-610Drug
IBIO-610; subcutaneous injection
PlaceboDrug
Matching placebo; subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assessment of the safety and tolerability of a single dose of IBIO-610; Incidence, severity, and relationship to study treatment of TEAEs and SAEs, as determined by clinical laboratory evaluations, vital signs, physical examinations, and ECGs.Time frame: From Day 1 through Day 252
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Q-Pharm Pty Ltd
Brisbane, Queensland, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.